Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mogamulizumab With DA-EPOCH or CHOEP in Aggressive T-cell Lymphoma
NCT05996185Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Oct 2024
- Primary completion
- Nov 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mogamulizumab in T-cell lymphoma, sponsored by Yale University. Started Oct 2024; status: recruiting.
02
Drugs
mogamulizumab
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT05996185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05996185.